Activator protein 1 (AP-1) transcription factor dimers are composed of Jun, Fos, and ATF member proteins, but the mechanisms that determine AP-1 composition are not clearly defined and the function of specific dimers is not well understood. MEKK1 is a mitogen-activated protein kinase (MAPK) kinase kinase and an ubiquitin ligase that regulates both the extracellular signal-regulated kinase 1/2 and the c-Jun amino-terminal kinase. Herein, we demonstrate that MEKK1 regulates the AP-1 protein repertoire. Both FGF-2 and phorbol ester-inducible urokinase-type plasminogen activator (uPA) expression requires AP-1 binding to an enhancer element in the uPA promoter, and we have previously shown that FGF-2 or PMA induction of uPA expression is strongly dependent on MEKK1. JunB mRNA is significantly increased in MEKK1À/À cells, demonstrating that MEKK1 suppresses JunB mRNA expression. Upregulation of JunB expression in MEKK1À/À cells forms an inhibitory AP-1 complex that binds to the uPA promoter and inhibits uPA transcription. MEKK1 also regulates Fra-2 protein stability by inducing Fra-2 ubiquitination and degradation. MEKK1 regulates AP-1-dependent gene expression by regulating the expression, activity and degradation of component members of the AP-1 complex. Controlling the repertoire of a transcription factor complex is a newly defined function for an MAPK kinase kinase.
Introduction
The activator protein 1 (AP-1) transcription factor binds DNA and regulates gene expression in response to a diverse array of stimuli (Angel and Karin, 1991; Shaulian and Karin, 2001) . Cellular growth, differentiation, and stress signals originating from these environmental conditions are transduced to the cell nucleus via activation of signaling pathways that induce AP-1 transcriptional complex formation (Shaulian and Karin, 2001) . AP-1 binds to DNA regulatory sequences called TPA-response elements (TRE) to regulate gene expression (Shaulian and Karin, 2001 ). For example, growth factor-induced expression of the secreted serine protease urokinase-type plasminogen activator (uPA) is strongly dependent on AP-1 complexes binding to a TREcontaining enhancer region 2.4 kb upstream of the transcriptional start site (D'Orazio et al., 1997) .
AP-1 dimers are comprised of Jun family protein (cJun, JunB, JunD) homodimers, or Jun heterodimers with Fos (c-Fos, FosB, Fra-1, Fra-2), or ATF family proteins (Angel and Karin, 1991; Shaulian and Karin, 2001) . While a variety of dimers could potentially be formed from this pool of factors, the Jun, Fos, and ATF proteins are not functionally interchangeable. For example, De Cesare and co-workers demonstrated that uPA expression specifically requires c-Jun and ATF-2, but not c-Fos (De Cesare et al., 1995) . There are also developmental distinctions between Jun family proteins, as both c-Jun and JunB are required for embryonic development, but JunD is not (Eferl et al., 1999; Jochum et al., 2001) . Defective cardiac development and neonatal lethality result when c-Jun is replaced by JunB in mice using a knockin strategy, thus demonstrating that JunB function cannot completely compensate for a lack of c-Jun (Passegue et al., 2002) . Conversely, JunB is absolutely required for placentation, and JunB-deficient embryos fail to establish adequate connections to maternal circulation (Schorpp-Kistner et al., 1999) . These JunB-deficient embryo trophoblast cells display dysregulated expression of uPA and matrix metalloproteinase (MMP)9 (Schorpp-Kistner et al., 1999) , thereby demonstrating that c-Jun and JunB have distinct roles in the control of gene expression. Indeed, JunB has been proposed to be antagonistic to AP-1-dependent gene expression that requires c-Jun (Chiu et al., 1989; Bakiri et al., 2000; Szabowski et al., 2000) . One example of the c-Jun/JunB dynamic is the AP-1-dependent regulation of cyclin D1 expression, where c-Jun activates the cyclin D1 promoter, but JunB inhibits transcription (Bakiri et al., 2000) .
AP-1-dependent gene expression impacts cell fate through the control of cell proliferation and death (Shaulian and Karin, 2001; Lamb et al., 2003) , and the importance of AP-1 regulation is underscored by both cfos and c-jun being cellular homologues of transforming viral oncogenes (Angel and Karin, 1991) . Studies with skin models have begun to elucidate the role of abnormal AP-1 regulation in tumorigenesis (Jochum et al., 2001) . Expression of c-Jun with mutated phosphoacceptor sites conferred resistance to Rasinduced papilloma formation (Behrens et al., 2000) . Further, ectopic Fra-1 expression enhances the invasiveness of mammary adenocarcinoma cells (Jochum et al., 2001) , while transgenic mice that express a dominant-negative form of c-Jun (TAM-67) are resistant to the tumor-promoting activity of okadaic acid (Thompson et al., 2002) and human papilloma virus (Young et al., 2002a) . If the potential consequences of dysregulation of AP-1 activity are severe, then it is not surprising that AP-1 protein is tightly regulated both transcriptionally and post-translationally (Karin et al., 1997) . Jun protein (and likely Fos proteins as well) stability and degradation are regulated by the ubiquitin/ proteasome system, and Jun protein ubiquitination and consequent AP-1 complex degradation disrupts AP-1-dependent transcription (Fuchs et al., 1996 (Fuchs et al., , 1997 Acquaviva et al., 2001 Acquaviva et al., , 2002 . Importantly, transcription of Fra-1, Fra-2, and c-Jun also require AP-1 activity (Karin et al., 1997; Murakami et al., 1999; Pepper, 2001; Young et al., 2002b; Casalino et al., 2003) , suggesting signaling pathways that activate AP-1 transcription factor complexes regulate expression of specific genes by controlling the composition of AP-1 dimers. Thus, the biochemical signals that alter AP-1 protein expression will, by extension, regulate expression of AP-1 targets. Important cellular functions are under AP-1 control, and significant diseases result from dysregulation of the AP-1 repertoire. Little is known about the regulation of the AP-1 repertoire and the mechanisms by which specific signaling pathways determine the specificity of AP-1 function.
uPA and related tissue plasminogen activator (tPA) cleave the inactive plasminogen zymogen to form active plasmin. Plasmin cleaves fibrin, and can activate MMP zymogens that then degrade extracellular matrix (ECM) proteins (Legrand et al., 2001; Pepper, 2001) . The control of plasmin-mediated ECM degradation is critical for homeostatic processes such as tissue remodeling (Collen, 2001) , liver regeneration (Roselli et al., 1998) , and mammary gland involution (Lund et al., 2000) , and dysregulation of plasminogen activator proteolysis has been linked to tumor progression and metastasis (Andreasen et al., 1997) . Indeed, expression of a mammary gland-specific MMP3 transgene alone resulted in tumor formation (Sternlicht et al., 1999) , whereas plasminogen-deficient mice are resistant to polyoma middle T transgene-induced lung metastasis (Bugge et al., 1998) .
Mitogen-activated protein kinases (MAPKs) have been shown to mediate signals resulting in AP-1-dependent gene expression (Angel and Karin, 1991; Karin et al., 1997) . AP-1 regulation may take place at the level of the post-translational phosphorylation, where c-Jun amino-terminal kinase (JNK) phosphorylates c-Jun and thereby enhances its ability to activate transcription (Karin et al., 1997) . MAPK signaling may also regulate the AP-1 proteins at the transcriptional level, as Fra-1 expression is significantly dependent on MAPK-induced AP-1 binding to a regulatory region within the first intron of the fra-1 gene (Casalino et al., 2003) . MAPK activity also results in phosphorylation and activation of Fra-2 (Murakami et al., 1999) . Recently, it has been demonstrated that MAPKdependent AP-1 phosphorylation affects protein stability, as Casalino and co-workers demonstrated that MEK/extracellular signal-regulated kinase (ERK)-mediated Fra-1 phosphorylation dramatically increased Fra-1 half-life in transformed thyroid cells (Casalino et al., 2003) . While it is well established that JNK phosphorylation of c-Jun enhances its transcriptional activity, it is currently unclear whether JNK-mediated phosphorylation targets AP-1 transcription factor components for ubiquitination (Fuchs et al., 1996 (Fuchs et al., , 1997 or protects them from ubiquitin/proteasome-mediated destruction (Musti et al., 1997; Fuchs et al., 2000) .
We gained insight into the regulation of AP-1 composition when we observed that uPA, a gene strongly dependent on AP-1 for transcription, is regulated by MEKK1. MEKK1 is an MAPK kinase kinase that regulates both the JNK and ERK1/2 signaling pathways (Yujiri et al., 1998) . Indeed, we have shown MEKK1 to be required for inducible uPA expression, and that control of both the JNK and ERK1/2 activities was necessary for this MEKK1 regulatory function . MEKK1 is both a kinase and an ubiquitin ligase, and autoubiquitination of MEKK1 inhibits its kinase activity . In this study, we demonstrate that MEKK1 modulates uPA expression through control of AP-1 dimer composition. The findings demonstrate how MEKK1 uniquely integrates the regulation of protein stability and transcriptional control of AP-1 components to regulate the AP-1 repertoire and the expression of an AP-1 target gene.
Results
Loss of MEKK1 expression alters composition of AP-1 complex bound to the uPA enhancer
We have recently shown MEKK1 to be required for PMA and FGF-2-dependent uPA transcription . Both FGF-2 and PMA stimulate binding of transcription factors to an enhancer region 2.4 kb upstream of the murine uPA transcriptional start site consisting of a pair of TRE separated by a 74-nucleotide protein-binding span named the cooperation mediator element (Cirillo et al., 1999) . Both the 5 0 -and 3 0 TRE are essential for PMA-induced uPA expression (Cirillo et al., 1999) . As MEKK1-deficient cells fail to upregulate uPA in response to PMA or FGF-2, we asked if the AP-1 components bound to the required TRE within the uPA enhancer of MEKK1-deficient fibroblasts were different than those of wild-type cells. To investigate the role of MEKK1 in determining the composition of AP-1 complexes, we compared the TREbinding proteins of nuclear extracts from MEKK1-deficient fibroblasts to those of wild-type cells by electrophoretic mobility shift assay (EMSA) (Figure 1a ). We developed EMSA probes that included the sequence from either the 5 0 -or 3 0 TRE, as well as a probe that combined the 5 0 -and 3 0 TRE separated by a four base linker. Under serum-starved conditions, all three probe sets combine with wild-type nuclear proteins to form complexes that differ markedly from those of MEKK1-deficient samples ( Figure 1a ). Nuclear extract samples from MEKK1 þ / þ cells combined with the 5 0 probe to produce a lower mobility complex that is absent or greatly reduced in MEKK1À/À EMSA samples ( Figure 1a) . Further, wild-type fibroblast nuclear proteins bound the 3 0 probe to produce two distinct complexes, whereas only the higher mobility complex was observed in the EMSA reaction using nuclear extracts from MEKK1-deficient cells ( Figure 1a) . The loss of a probe/protein complex is a result consistent with an altered set of proteins binding to the 5 0 -and 3 0 TRE, and suggests that the transcription factor complexes bound to the uPA enhancer of MEKK1-deficient fibroblasts are different than those from wild-type cells.
Cirillo and co-workers demonstrated that c-Jun/ATF-2 heterodimers bind to the uPA 5 0 TRE enhancer sequence in response to PMA (Cirillo et al., 1999) . We have shown that uPA expression induced by either PMA or FGF-2 is blocked in MEKK1À/À cells. We therefore performed EMSA analysis using FGF-2-stimulated wild-type and MEKK1À/À fibroblast nuclear extracts to determine if the protein complexes bound to the 5 0 TRE were altered in MEKK1-deficient cells. As predicted, the FGF-2-stimulated MEKK1-deficient nuclear extracts exhibited an EMSA profile markedly different from that of the MEKK1 þ / þ cells ( Figure 1a ). In order to determine if the observed differences in DNA-bound complex electrophoretic mobility was due to altered AP-1 composition, we performed supershift analysis using antibodies to AP-1 proteins to identify the transcription factors bound to the 5 0 TRE probe. Our analysis confirmed that ATF-2 bound the 5 0 TRE of both wild-type and MEKK1À/À cells. In addition, we found that antibodies to JunB combined with the probe/protein complex to form a prominent supershifted band in MEKK1-deficient cells ( Figure 1b shows the supershifted bands above the EMSA complexes), and this intense band was not evident in reactions from wild-type cell extracts. We were unable to detect equally prominent supershifted bands with antibodies to c-Jun, possibly due to inadequate antibody affinity coupled with the background that we encountered in the fibroblasts with this probe. To confirm that MEKK1 could regulate the composition of AP-1 proteins that bound the uPA enhancer in vivo, we immunoprecipitated AP-1 proteins linked to DNA sequences by formalin fixation of FGF-2-treated fibroblasts. We then performed PCR to amplify the associated DNA with primers that flanked the 5 0 TRE. Chromatin immunoprecipitation (CHIP) confirms that c-Jun is bound to the uPA enhancer in wild-type cells (Figure 1c) , as is ATF-2. Strikingly, the uPA enhancer of MEKK1-deficient cells differs from that of MEKK1 þ / þ cells in that JunB binds the enhancer of MEKK1À/À cells at a level similar to that 0 of uPA start site is assessed by EMSA (a and b) or CHIP (c). (a) Cells were serum starved for 24 h (left box), and then stimulated with 10 ng/ml FGF-2 for 5 h (far right lanes) before nuclear extracts were harvested. MEKK1 þ / þ and MEKK1À/À MEF nuclear extracts are incubated with labeled probe consisting of either the 5 0 TRE, the 3 0 TRE, or a combined probe that includes both TRE linked by a four base sequence. Arrow indicates wildtype transcription factor/probe complexes, arrowhead indicates MEKK1À/À transcription factor/probe complex. (b and c) Serumstarved cells were treated for 5 h with 10 ng/ml FGF-2. (b) MEKK1 þ / þ and MEKK1À/À MEF nuclear extracts are incubated with 5 0 TRE probe and antibodies to AP-1 components. Arrowhead indicates supershift (SS). (c) CHIP was performed as described in Materials and methods with the antibodies listed or with protein A agarose beads alone as a control. Data are representative of at least three independent experiments of c-Jun (Figure 1c) . Cumulatively, our data from the EMSA and CHIP assays demonstrate that MEKK1 regulates the composition of AP-1 transcriptional complexes that bind the uPA enhancer.
Jun/Fos family protein expression is altered in MEKK1-deficient fibroblasts
Since we observed that the AP-1 dimers bound to DNA in MEKK1À/À cells differed from those of wild-type cells, we wanted to determine if individual AP-1 component expression was altered in MEKK1-deficient cells. It has been well documented that posttranslational modification of Jun proteins by MAPK affects transcriptional activation (Karin et al., 1997) . Alternately, MAPK signaling can regulate AP-1 proteins at the transcriptional level, as c-Fos expression is upregulated by ERK1/2-dependent phosphorylation of Elk-1 and its subsequent binding to the serumresponse element within the c-Fos promoter (Angel and Karin, 1991) . As our results demonstrate that the AP-1 proteins bound to the uPA enhancer differ in MEKK1À/À vs wild-type cells, we asked if this change was due to an altered AP-1 repertoire. We performed Western blot analysis using nuclear extracts from both-wild type and MEKK1 knockout cells, and discovered that MEKK1À/À cells display striking changes in AP-1 component protein levels (Figure 2 ). JunB protein expression is markedly increased in MEKK1À/À nuclear extracts (Figure 2) , a result consistent with our supershift and CHIP assays that clearly showed JunB to be bound to the uPA enhancer of MEKK1À/À cells (Figure 1 ). Fra-2 expression is also greatly enhanced in the MEKK1-deficient cells (Figure 2 ), whereas ATF-2 and c-Jun protein levels were similar between the two cell populations. Further, the contrast in JunB and Fra-2 expression levels remained consistent even in FGF-2-or PMA-stimulated cells (Figure 2a and b) .
To determine if the elevated expression of JunB and Fra-2 observed in MEKK1-deficient cells was due to enhanced transcription, we performed RNAse protection assay (RPA) analysis using RNA from both resting and FGF-2-stimulated fibroblasts. We found that JunB mRNA was markedly increased in resting or FGF-2-stimulated MEKK1À/À compared to wild-type cells. Serum-starved MEKK1-deficient fibroblasts displayed significantly enhanced levels of both JunB and Fra-2 mRNA, and the JunB RNA disparity between MEKK1À/À and wild-type cells remained intact even after FGF-2 stimulation (Figure 3a and b) . Importantly, the JunB and Fra-2 mRNA was restored to wild-type levels in knockout cells transfected with MEKK1 (addback), demonstrating that this phenotype was due to MEKK1 deficiency. Interestingly, while Fra-2 protein levels were markedly increased in stimulated MEKK1À/ À cells (Figure 2 ), Fra-2 mRNA levels of FGF-2-stimulated MEKK1À/À cells were not significantly greater than those of wild-type cells (Figure 3a and b) . Fra-2 protein levels remain enhanced in MEKK1-deficient cells despite mRNA levels being similar to wild-type cells suggesting that an additional regulatory mechanism controls Fra-2 expression.
MEKK1 activity regulates AP-1 protein degradation
We have observed significantly increased basal Fra-2 mRNA levels from MEKK1À/À vs wild-type fibroblasts, but in stimulated cells this difference was modest (Figure 3) . Surprisingly, in FGF-2-or PMA-stimulated MEKK1À/À cells, Fra-2 was expressed at markedly greater levels than in wild-type cells (Figure 2 ). This result suggested that Fra-2 might be more stable in the absence of MEKK1. Some Fos proteins, as well as both c-Jun and JunB, have been shown to be regulated by ubiquitin/proteasome-mediated degradation (Fuchs et al., 1997; Acquaviva et al., 2001) . MEKK1 has E3 ubiquitin ligase activity, and we have recently demonstrated that this E3 activity can regulate MEKK1-dependent MAPK activation . To determine if MEKK1 induces AP-1 protein ubiquitination, we coexpressed myc-tagged ubiquitin with MEKK1 and AP-1 expression constructs and assessed ubiquitination by immunoblot analysis. When coexpressed with MEKK1, Fra-2 displayed a dramatic electrophoretic mobility shift compared to control and was ubiquitinated (Figure 4a and b) . In contrast, JunB and c-Jun did not display a visible mobility shift and were only modestly ubiquitinated when coexpressed with MEKK1 (Figure 4b ), suggesting MEKK1 does not significantly stimulate c-Jun or JunB ubiquitination. As ubiquitination often induces proteasome-mediated protein degradation, we asked if the increased Fra-2 protein content of MEKK1À/À cells was due to reduced MEKK1-dependent Fra-2 degradation. We treated wild-type, MEKK1À/À, and MEKK1À/À add-back fibroblasts with the proteasome inhibitor MG132 to prevent protein degradation, and then performed immunoblot analysis to determine if MEKK1 regulated endogenous AP-1 protein stability. In MEKK1À/À cells, Fra-2 was markedly more stable than in wild-type cells (Figure 4c) , and Fra-2 degradation was restored in the MEKK1À/À add-back cells to levels similar to wild-type cells. Fra-2 protein concentration was similar in all three cell types treated with MG132, demonstrating that the difference in Fra-2 expression is due to proteasome-mediated Fra-2 degradation (Figure 4c ). In contrast, JunB levels were not altered in the presence of MG132, thus demonstrating that the disparity in JunB levels between wild-type and MEKK1À/À cells is independent of the proteasome, and is consistent with MEKK1 regulating JunB transcription, but not JunB ubiquitination and destruction (Figure 4c ). c-Jun protein levels of all three cell types were increased by treatment with MG132, and the c-Jun concentration was similar between the untreated cell populations. This result indicates that, while c-Jun is subject to proteasome-mediated destruction, this process is not regulated by MEKK1. ATF-2 protein expression was similar between the three cell populations, showing ATF-2 protein levels are not controlled by MEKK1. Importantly, Fra-2 and JunB levels similar to those of wild-type cells were observed in MEKK1À/À add-back cells (Figure 4c ), demonstrating that their dysregulation was due to a loss of MEKK1 expression. Taken together, our data are consistent with MEKK1 selectively regulating Fra-2 protein stability.
MEKK1 autoubiquitination regulates its kinase activity . Surprisingly, Fra-2 coexpressed with a MEKK1 mutant form that lacks E3 activity (C441A) also became ubiquitinated, but Fra-2 coexpressed with a kinase-inactive MEKK1 (K1253M) did not (Figure 4a and b) . This result demonstrates that MEKK1 kinase activity, but not E3 ligase activity, is necessary for Fra-2 ubiquitination. Thus, MEKK1 controls the AP-1 repertoire by regulating both the transcription and degradation of specific AP-1 component proteins. When Passegue and co-workers replaced c-jun with junB using a knockin strategy, fibroblast uPA expression was drastically reduced, demonstrating that c-Jun is required for uPA expression and that JunB could not substitute for c-Jun in uPA induction (Passegue et al., 2002) . Our analysis suggests that dimers that include JunB and Fra-2 are more abundant in MEKK1-deficient cells (Figures 1 and 2 ). To determine if increased expression of JunB or Fra-2 inhibits uPA expression, we developed wild-type cell lines with stable expression of either protein and assessed uPA induction by Northern blot analysis. We observed that wild-type cells that overexpress JunB, but not Fra-2 or c-Jun, show markedly reduced FGF-2-induced uPA expression (Figure 5a ). Despite lower protein levels, we found that Fra-2 bound the uPA enhancer in wild-type cells (Figure 1b) , and increased Fra-2 protein levels did not inhibit uPA expression (Figure 5a ). We next examined the effect of increased JunB expression on the composition of AP-1 complexes bound to the uPA enhancer in vivo by CHIP analysis, and as predicted found that the reduced uPA induction was concomitant with increased JunB binding to the uPA enhancer (Figure 5b ). Importantly, the reduced uPA mRNA level in JunBoverexpressing cells mirrored that of MEKK1-deficient cells (Figure 5a ). Our data indicate that JunB has an inhibitory role in uPA gene expression, and are consistent with the loss of uPA induction in MEKK1À/À cells being due to increased JunB expression and participation in AP-1 complexes that bind to the uPA promoter. Immunoblot analysis of transfected HEK293 cell lysates. (a) FLAG epitope-tagged fra-2 was transfected into HEK293 cells with either an MEKK1 expression vector or empty vector. MEKK1/K1253M is a kinase-inactive mutant, MEKK1/C441A is an E3 ligase defective mutant. Proteins were separated by SDS-PAGE and Fra-2 detected by anti-FLAG immunoblot. (b) FLAG epitope-tagged c-jun, junB, or fra-2 was cotransfected with Myc epitope-tagged ubiquitin and MEKK1 expression constructs. Prior to lysis, the cells were treated with 20 mM proteasome inhibitor MG132 for 5 h. Ubiquitinated proteins were immunoprecipitated with anti-Myc antibodies and detected by anti-FLAG immunoblot. Jun/Fra expression was assessed by anti-FLAG immunoblot, and MEKK1 expression detected by anti-MEKK1 immunoblot. (c) Immunoblot analysis of MEKK1 þ / þ , MEKK1À/À, and addback fibroblast nuclear extracts. Cells were treated with 20 mM proteasome inhibitor MG132 for 5 h. Data are representative of at least three independent experiments Figure 5 JunB or Fra-2 overexpression inhibits uPA induction. uPA induction in MEKK1 þ / þ cells stable transfectants overexpressing JunB mimics that of MEKK1À/À fibroblasts. (a) Northern blot analysis of MEKK1À/À, and c-jun, junB, fra-2, or vector-transfected MEKK1 þ / þ fibroblasts treated with 10 ng/ml FGF-2 for 24 h. uPA induction was detected by hybridization with a labeled uPA cDNA probe. Equal RNA loading was verified by hybridization with beta-actin probe. (b) Serum-starved cells were treated for 5 h with 10 ng/ml FGF-2, and CHIP was performed as described in Materials and methods with the antibodies listed or with protein A agarose beads alone as a control. Data are representative of at least three independent experiments MEKK1 regulates AP-1 composition BD Cuevas et al Discussion AP-1 is a transcription factor that functions in the regulation of gene expression in response to diverse stimuli, including growth factor receptor ligation, cell stress, and cytoskeletal changes. MEKK1 is an MAPK kinase kinase that also is activated in response to these stimuli, and we investigated the role of MEKK1 in AP-1-dependent gene expression. The AP-1 dimer consists of Jun and Fos family proteins, but can include ATF family proteins as well. Unlike Fos, Jun proteins may form homodimers, or heterodimerize with Fos, or ATF proteins (Angel and Karin, 1991) . Thus, with multiple members available in each family, there is the potential for a number of different AP-1 dimers in the cell nucleus. However, published reports demonstrate that different AP-1 combinations are not functionally equivalent, and depending on the cellular context, some AP-1 combinations have been found to inhibit transcription. For example c-Jun/c-Fos dimers were markedly more effective at activating transcription of collagenase than c-Jun/Fra-2 or c-Jun/ATF-2 dimers (Bakiri et al., 2002) . Conversely, c-Jun/c-Fos dimers may act as a repressor of uPA expression if bound to the 5 0 TRE within the uPA enhancer, but a c-Jun/ATF-2 dimer activates transcription of uPA (De Cesare et al., 1995) . This is consistent with specific complexes being required for the expression of some genes, but not others. Thus, while TREs are found in a number of gene promoters, specificity of action is attained through functional diversity of the different AP-1 protein components and through signaling pathways that may activate or suppress those components. This specificity is particularly important considering that AP-1 has been linked to the highly regulated pathways necessary for cell proliferation, survival, and death, and disruption of mechanisms that control AP-1-dependent gene expression could thereby contribute to cellular transformation.
Both ERK1/2 and JNK signaling can regulate AP-1 dimers. ERK1/2 activity is involved in transcription of Fos family proteins c-Fos and Fra-1. Ets family transcription factor Ets-2 is an essential component of the transcriptional complex that binds the uPA enhancer (Cirillo et al., 1999) , and ERK1/2 phosphorylates the Ets-2 transcription factor, thereby enhancing Ets-dependent uPA expression (O'Hagan et al., 1996; Yang et al., 1996) . ERK1/2 activity is necessary for Fra-1 phosphorylation and consequent stabilization (Casalino et al., 2003) , and Fra-2 expression is also positively regulated by ERK1/2 phosphorylation (Murakami et al., 1999) . JNK can enhance the transcriptional activity of c-Jun by phosphorylation, but does not phosphorylate JunB, and phosphorylates JunD inefficiently (Kallunki et al., 1996) . Further, JNK activity may have a role in determining the stability of its substrates, suggesting that JNK activity is important for both positive and negative regulation of its transcription factor targets.
We have found MEKK1 to regulate both the ERK1/2 and JNK pathways. Thus, MEKK1 is uniquely situated to regulate AP-1 expression and activity as opposed to an MAPK kinase kinase that regulates a single MAPK pathway. This contention is supported by our data showing increased JunB expression in MEKK1-deficient cells. Our data demonstrate that MEKK1 suppresses JunB expression, although the mechanism of MEKK1-dependent transcriptional suppression is unclear. The control of JunB transcription is complex, potentially involving diverse families of transcription factors, and clarifying the role of MEKK1 in the regulation of this process is a subject of ongoing study in our laboratory. Loss of MEKK1 also impacts AP-1 proteins at the post-translational level, as Fra-2 protein is more stable in MEKK1À/À cells. As Fra-2 expression may be enhanced through a positive autoregulatory loop (Murakami et al., 1999) , reduced protein degradation may actually lead to an increase in Fra-2 transcription in MEKK1-deficient cells, and this may explain our observation that Fra-2 mRNA of resting MEKK1À/À cells is significantly increased (Figure 3b ). MEKK1-deficient fibroblasts display increased expression of JunB and Fra-2, potentially reducing AP-1 dimers that include c-Jun, while increasing the proportion of dimers that include JunB and Fra-2. Overexpression of Fra-2 in transgenic mice or conditional inactivation of c-Jun in mouse keratinocytes both result in eyelid fusion failure and pups born with open eyes (McHenry et al., 1998; Zenz et al., 2003) , a trait we have previously reported in MEKK1-deficient mice (Yujiri et al., 2000) . Intriguingly, our concurrent studies with MEKK2-deficient mice suggest that MEKK2 is also capable of regulating AP-1 component gene expression (Kesavan et al., 2004) , providing the foundation of a powerful argument that the MEKKs represent a family of MAPK kinase kinases that can specifically regulate AP-1-dependent gene expression. MEKK1 and MEKK2 null mice, by virtue of their altered AP-1 component milieu, represent very useful models to begin to define the transcriptional activity of specific AP-1 pairs. Further, both MEKK1 and MEKK2 knockout mice are viable and fertile, suggesting that either protein could be a useful therapeutic target for pathologies involving AP-1-mediated gene expression, such as inflammation and skin cancer.
uPA induction requires AP-1 binding to the enhancer, and our data are consistent with MEKK1 regulating uPA through control of the necessary AP-1 components needed to make a suitable transcriptional complex. In the absence of MEKK1, JunB expression is markedly increased, thereby elevating the proportion of AP-1 transcription factor dimers that include JunB and are not functional for the production of uPA (Figure 6 ).
MEKK1 activity can regulate AP-1 protein availability through post-translational mechanisms. We have demonstrated that MEKK1 activity leads to degradation of Fra-2. While MEKK1 has ubiquitin ligase activity, MEKK1 E3 ligase activity is not required for this function, but MEKK1 kinase activity is essential. Members of both the Jun and Fos families have been shown to be regulated by ubiquitin-dependent degradation (Fuchs et al., 1996 (Fuchs et al., , 1997 Acquaviva et al., 2001 Acquaviva et al., , 2002 . We did not observe direct ubiquitination of the Fra-2 by MEKK1, so these results are consistent with MEKK1 phosphorylation-dependent activation of an Fra-2 degradation pathway, possibly through activation of a different ubiquitin ligase. Alternately, MEKK1-mediated MAPK activation may target MAPK substrates for ubiquitination and degradation.
We have demonstrated that the MEKKs may exert control over gene expression by regulating the supply of required transcriptional machinery. The Jun and Fos proteins were first identified through isolation of their viral oncogene homologues (Angel and Karin, 1991) , and altered regulation of AP-1 transcriptional activity has been linked to skin cancer (Angel et al., 2001 ) and leukemia (Jochum et al., 2001) . Our data suggest that an exciting potential avenue for therapeutic control of AP-1-dependent processes exists through development of small molecule MEKK inhibitors.
Materials and methods

Antibodies and reagents
The antibodies against AP-1 proteins were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). The anti-uPA antibody was a generous gift of the Finsen Laboratory (Denmark). The RPA probe set was purchased from BD Biosciences PharMingen (San Diego, CA, USA). uPA Northern blot probe and procedure was described previously .
Cell lines
Immortalized mouse embryo fibroblasts (MEFs) were obtained as described previously (Yujiri et al., 2000) .
Cell culture, stimulation, and lysis
MEFs were cultured in IMDM medium (GIBCO, Grand Island, NY, USA) containing penicillin/streptomycin (1%, GIBCO), and 10% (v/v) fetal calf serum (Gemini Bioproducts, Woodland, CA, USA) at 371C in a humidified atmosphere. Human FGF-2 was purchased from Upstate Cell Signaling Solutions. PMA was purchased from Sigma. Lysis for postnuclear detergent cell extracts was described previously .
Nuclear extracts and EMSA
Cells were washed in phosphate-buffered saline, collected in homogenization buffer (10 mM HEPES (pH 7.9), 10 mM KCl, 1.5 mM MgCl 2 , 0.1 mM EGTA, 0.5 mM dithiothreitol) using a cell scraper, and disrupted by passage through a 25-gauge needle. Nuclei were collected by centrifugation, washed twice with homogenization buffer, and resuspended in an equal volume of extraction buffer (10 mM HEPES (pH 7.90, 0.4 M NaCl, 1.5 mM MgCl 2 , 0.1 mM EGTA, 0.5 mM dithiothreitol), shaken at 41C for 15 min, centrifuged at 41C for 15 min, and supernatant was harvested for EMSA and immunoblot analysis. The protease inhibitors leupeptin (10 mM), aprotinin (1.5 mM), PMSF (2 mM), and pepstatin A (10 mM) were included in both the homogenization and extraction buffers. Labeled probe was mixed with nuclear extracts at room temperature for 15 min and separated by 8% nondenaturing gel. The sequences of the oligonucleotide probes were both derived from the murine uPA promoter: 5 0 TRE, 5 0 -CCAGGAGGAAATGAGGTCATCTTGCTC-3 0 ; 3 0 TRE, 5 0 -GGGGCCATGTGAATCACGACAGCCTGC-3 0 ; and combined, 5 0 -CTCTGGCCAGGAGGAAATGAGGTCATCTGTG AATCACGACAGCCT-3 0 .
Chromatin immunoprecipitation
CHIP assay kit was purchased from Upstate Cell Signaling Solutions (Lake Placid, NY, USA) and assays were carried out according to the manufacturer's recommendations. DNA was fractured by sonication to yield 1 kb fragments, and AP-1/DNA complexes were immunoprecipitated with 2 mg of antibody. PCR was performed using Platinum Taq (Invitrogen) for 35 cycles. Primers were designed to amplify the region surrounding the 5 0 TRE of the murine uPA enhancer (À2450 to À2435), and produce a 317 bp fragment (À2689 to À2372).
Transient transfection
Adherent cells were transfected by lipofection as described previously . Constructs for c-jun and junB (pBABE) were generous gifts of Erwin Wagner. The fra-2 (pCDNA3) mammalian expression construct was a generous gift of Nancy Colburn. MEKK1 expression constructs were described previously . 
